Related Experiment Videos
Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: clinical aspects
H N Hodis1, W J Mack, R M Krauss
1Atherosclerosis Research Unit, Division of Cardiology, University of Southern California School of Medicine, Los Angeles 90033, USA.
Insights
Triglyceride-rich lipoproteins (TRL) drive mild-to-moderate atherosclerosis progression, even with low-density lipoprotein cholesterol (LDL-C) reduction. Targeting TRL offers a new strategy to slow coronary artery disease progression.
Area of Science:
- Cardiovascular Medicine
- Atherosclerosis Research
- Lipid Metabolism
Background:
- Atherosclerosis progression persists despite aggressive low-density lipoprotein cholesterol (LDL-C) reduction.
- Triglyceride-rich lipoproteins (TRL) are implicated in the progression of mild-to-moderate atherosclerotic lesions.
- Current therapies primarily focus on LDL-C, with limited impact on certain lesion types.
Purpose of the Study:
- To evaluate the role of TRL in atherosclerosis progression.
- To compare the impact of TRL lowering versus LDL-C lowering on coronary artery disease (CAD) progression.
- To highlight TRL as a therapeutic target for managing mild-to-moderate atherosclerotic lesions.
Main Methods:
- Review of serial coronary angiography trials.
- Analysis of quantitative coronary angiography (QCA) data.
- Evaluation of TRL and apolipoprotein markers in relation to lesion severity.
Main Results:
- Lowering LDL-C effectively retards progression of severe lesions (≥50% diameter stenosis).
- TRL significantly contribute to the progression of mild-to-moderate lesions (<50% diameter stenosis).
- Progression of mild-to-moderate lesions is a key predictor of clinical coronary events.
Conclusions:
- TRL are a critical factor in the progression of mild-to-moderate coronary artery disease.
- Lowering TRL levels reduces CAD progression comparably to lowering LDL-C.
- Targeting TRL represents a promising therapeutic strategy for comprehensive atherosclerosis management.
Abstract:
Invasive and noninvasive arterial imaging are important techniques used to study atherosclerosis and, specifically, to evaluate the atherogenecity of triglyceride-rich lipoproteins (TRL). Serial coronary angiography trials show significant benefit from lowering low-density lipoprotein cholesterol (LDL-C) which serves to retard lesion progression. Even with aggressive LDL-C reduction, however, up to half of patients demonstrate continued progression of atherosclerosis. Angiographic studies reveal that lowering LDL-C has the most impact on severe lesions, those > or = 50% diameter stenosis, whereas TRL (and their apolipoprotein markers) have been identified as a driving factor behind progression of mild-to-moderate lesions < 50% diameter stenosis. Quantitative coronary angiography (QCA) has demonstrated that progression of mild-to-moderate lesions are among the most significant predictors of clinical coronary events, and that lowering TRL reduces progression of coronary artery disease to the same degree as the lowering of LDL-C.